Table 3.
Proportion of hrHPV at screeninga among long-term non-attenders in total and by intervention arm.
| Control | Opt-in | Send-to-all | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Type of HPV screening test | N | N | Any HR positiveb, n (%) | 16/18 positivec, n (%) | Other HR positived, n (%) | N | Any HR positiveb, n (%) | 16/18 positivec, n (%) | Other HR positived, n (%) | N | Any HR positiveb, n (%) | 16/18 positivec, n (%) | Other HR positived, n (%) |
| Total | 913 | 84 | 5 (6.0) | 0 (0.0) | 4 (4.8) | 314 | 34 (10.8) | 11 (3.5) | 23 (7.3) | 515 | 61 (11.8) | 27 (5.3) | 33 (6.4) |
| Clin-sample | 218 | 84 | 5 (6.0) | 0 (0.0) | 4 (4.8) | 64 | 7 (10.9) | 2 (3.1) | 5 (7.8) | 70 | 8 (11.4) | 3 (4.3) | 4 (5.7) |
| Self-sample | 695 | – | – | – | – | 250 | 27 (10.8) | 9 (3.6) | 18 (7.2) | 445 | 53 (11.9) | 24 (5.4) | 29 (6.5) |
aWomen who attended clinician screening with a primary cytology test (n = 20) are not included. Six of these were in the control group, nine in the opt-in group and five in the send-to-all group.
bPositive for one or more of the hrHPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 or 68. Two women (one control and 1 send-to-all) were registered as any hrHPV-positive, but lacked information on hrHPV-type.
cPositive for HPV16 and/or 18, and may be positive for other hrHPV types.
dPositive for one or more of the hrHPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 or 68, but negative for 16/18.